COMP <GO>
ANIX vs CLLS // EV/EBITDA & P/E VALUATION
Anixa Biosciences Inc. (NASDAQ) VS. Cellectis S.A. (NASDAQ) • 15-METRIC TALLY: ANIX 1
— CLLS 1
■ METRIC PARITY
LAST: $3.12 (-5.45%) • MKT CAP: $114.7M
valuation
—
LAST: $1.08 (-7.69%) • MKT CAP: $117.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIX VS. CLLS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIX | CLLS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.25% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.3 | 37.6 | +18.67 | ANIX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $114.7M | $117.6M | -$2.9M | CLLS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIX REV | CLLS REV | ANIX GROSS % | CLLS GROSS % | ANIX FCF | CLLS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$7.2M | — |
| FY 2024 | $210.0K | — | — | — | -$7.3M | — |
| FY 2023 | $210.0K | — | — | — | -$6.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIX // BETA —
CLLS // BETA —